|Bid||73.45 x 300|
|Ask||73.47 x 300|
|Day's Range||73.30 - 73.99|
|52 Week Range||63.76 - 88.85|
|PE Ratio (TTM)||7.76|
|Dividend & Yield||2.08 (2.82%)|
|1y Target Est||N/A|
Gilead Sciences Inc. said early Monday that its HIV combination treatment had similar safety and efficacy results in two late-stage clinical trials to the standard of care. The data, along with two other ...
Three decades after approval of the first-ever AIDS treatment, HIV medicine is seeing a new wave of innovation with scientists reporting positive data on Monday for improved drug cocktails and a novel experimental vaccine. The Achilles heel for us is drug resistance because the virus is incredibly quick to mutate," Linda-Gail Bekker, deputy director of the Desmond Tutu HIV Centre in South Africa, said. The race for better and more convenient medicines has made HIV a rich battleground for drug companies such as Gilead Sciences and GlaxoSmithKline, which generate billions of dollars from modern therapies.
But this needs to heat up again for the sector to rally in a big way.